Medicus Pharma reports validation of SkinJect skin cancer trial data
Tweet Send to a Friend
Medicus Pharma Ltd. (NASDAQ: MDCX) announced that Dr. Babar Rao, principal investigator of its Phase 2 SkinJect trial, validated the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
